Yupelri and Trelegy are both inhaled medications used to treat respiratory conditions, but they are approved for different primary indications and have different active ingredients.
What is Yupelri approved to treat?
Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) [1]. It works by relaxing the muscles around the airways in the lungs, making it easier to breathe [1].
What is Trelegy approved to treat?
Trelegy (fluticasone furoate/umeclidinium/vilanterol) is a combination inhaler containing three active ingredients: an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-agonist (LABA) [2]. It is approved for the maintenance treatment of patients with COPD, and also for the long-term control of asthma in patients aged 12 years and older who are not adequately controlled on a long-term asthma medication that combines an ICS and a LABA [2].
How do Yupelri and Trelegy differ in their active ingredients?
Yupelri contains a single active ingredient, revefenacin [1]. Trelegy is a triple therapy, combining fluticasone furoate (an ICS), umeclidinium (a LAMA), and vilanterol (a LABA) [2]. This means Trelegy addresses inflammation (with the ICS) in addition to bronchodilation (with the LAMA and LABA), whereas Yupelri primarily focuses on bronchodilation.
Can Yupelri be used for asthma?
Yupelri is not approved for the treatment of asthma [1]. Trelegy, on the other hand, is approved for both COPD and asthma [2].
How are Yupelri and Trelegy administered?
Both Yupelri and Trelegy are administered via inhalation, typically once daily [1][2]. Yupelri is delivered using a specific eFlow nebulizer system [1]. Trelegy is administered using the Ellipta inhaler device [2].
When do the patents for Yupelri and Trelegy expire?
Patent expiry dates for medications can be complex and vary depending on specific patents and any legal challenges. Information on patent expiration for specific drugs can be found on sites like DrugPatentWatch.com [3]. For Yupelri, the patent landscape is related to revefenacin. For Trelegy, there are patents covering its individual components and the combination product. These patents are crucial for determining when generic versions of these medications may become available.